Scroll

meropenem 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
analogues of penicillanic acid antibiotics modified in the five-membered ring	1709	96036-03-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: meropenem hydrate meropenem merrem meropenem trihydrate	an antibacterial drug readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets, the bactericidal activity of meropenem results from the inhibition of cell wall synthesis Molecular weight: 383.46 Formula: C17H25N3O5S CLOGP: -2.29 LIPINSKI: 0 HAC: 8 HDO: 3 TPSA: 110.18 ALOGS: -1.83 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

meropenem hydrate
meropenem
merrem
meropenem trihydrate

an antibacterial drug readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets, the bactericidal activity of meropenem results from the inhibition of cell wall synthesis

Molecular weight: 383.46
Formula: C17H25N3O5S
CLOGP: -2.29
LIPINSKI: 0
HAC: 8
HDO: 3
TPSA: 110.18
ALOGS: -1.83
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	g	P
3	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	70 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	3.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	111.76 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
t_half (Half-life)	1 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.87 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.30 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
June 21, 1996	FDA	ASTRAZENECA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	683.41	17.94	409	33888	56343	63398382
Septic shock	567.58	17.94	386	33911	66243	63388482
Drug reaction with eosinophilia and systemic symptoms	438.81	17.94	256	34041	33580	63421145
Drug resistance	403.01	17.94	212	34085	22721	63432004
Pathogen resistance	367.17	17.94	136	34161	6262	63448463
Sepsis	291.11	17.94	385	33912	152738	63301987
Respiratory failure	246.18	17.94	289	34008	101569	63353156
Febrile neutropenia	234.57	17.94	304	33993	118145	63336580
Thrombocytopenia	224.76	17.94	338	33959	150819	63303906
Pain	218.62	17.94	65	34232	740563	62714162

Showing 1 to 10 of 335 entries

Previous1 2 3 4 5…34Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	572.48	14.90	594	44565	75972	34835800
Septic shock	493.69	14.90	533	44626	71301	34840471
Drug resistance	407.48	14.90	307	44852	25620	34886152
Pathogen resistance	393.75	14.90	208	44951	9274	34902498
Drug ineffective	350.48	14.90	1334	43825	455417	34456355
Drug reaction with eosinophilia and systemic symptoms	340.43	14.90	306	44853	32706	34879066
Bronchopulmonary aspergillosis	235.58	14.90	176	44983	14483	34897289
Off label use	219.10	14.90	1093	44066	418431	34493341
Fatigue	211.53	14.90	108	45051	370545	34541227
Respiratory failure	206.61	14.90	442	44717	108130	34803642

Showing 1 to 10 of 356 entries

Previous1 2 3 4 5…36Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	1163.22	14.06	936	73754	119310	79550388
Septic shock	972.80	14.06	852	73838	121949	79547749
Drug resistance	781.78	14.06	489	74201	41724	79627974
Drug reaction with eosinophilia and systemic symptoms	751.06	14.06	560	74130	63684	79606014
Pathogen resistance	711.83	14.06	321	74369	14021	79655677
Drug ineffective	468.40	14.06	2121	72569	1078792	78590906
Sepsis	411.60	14.06	829	73861	268599	79401099
Respiratory failure	394.89	14.06	650	74040	180261	79489437
Bronchopulmonary aspergillosis	379.51	14.06	245	74445	22049	79647649
Pyrexia	361.11	14.06	1420	73270	677289	78992409

Showing 1 to 10 of 592 entries

Previous1 2 3 4 5…60Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01DH02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
ATC	J01DH52	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:33282	bactericides
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 7 of 7 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Streptococcal meningitis	indication	4510004	DOID:11574
Infection due to Pseudomonas aeruginosa	indication	11218009
Peritonitis	indication	48661000
Pneumococcal meningitis	indication	51169003
Abdominal abscess	indication	75100008
Bacterial meningitis	indication	95883001	DOID:9470
Infectious disease of abdomen	indication	128070006
Neisseria meningitidis meningitis	indication	192644005
Complicated appendicitis	indication	418171008
Peptostreptococcus Complicated Appendicitis	indication

Showing 1 to 10 of 47 entries

Previous1 2 3 4 5Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.79	acidic
pKa2	8.04	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1GM/VIAL;1GM/VIAL	VABOMERE	REMPEX	N209776	Aug. 29, 2017	RX	POWDER	INTRAVENOUS	10183034	Aug. 8, 2031	TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
1GM/VIAL;1GM/VIAL	VABOMERE	REMPEX	N209776	Aug. 29, 2017	RX	POWDER	INTRAVENOUS	10561675	Aug. 8, 2031	TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
1GM/VIAL;1GM/VIAL	VABOMERE	REMPEX	N209776	Aug. 29, 2017	RX	POWDER	INTRAVENOUS	11007206	Aug. 8, 2031	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
1GM/VIAL;1GM/VIAL	VABOMERE	REMPEX	N209776	Aug. 29, 2017	RX	POWDER	INTRAVENOUS	9694025	Aug. 8, 2031	TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
1GM/VIAL;1GM/VIAL	VABOMERE	REMPEX	N209776	Aug. 29, 2017	RX	POWDER	INTRAVENOUS	11376237	April 6, 2039	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED

Showing 1 to 5 of 5 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1GM/VIAL;1GM/VIAL	VABOMERE	REMPEX	N209776	Aug. 29, 2017	RX	POWDER	INTRAVENOUS	Aug. 29, 2022	NEW CHEMICAL ENTITY
1GM/VIAL;1GM/VIAL	VABOMERE	REMPEX	N209776	Aug. 29, 2017	RX	POWDER	INTRAVENOUS	Aug. 29, 2027	GENERATING ANTIBIOTIC INCENTIVES NOW

Showing 1 to 2 of 2 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D-alanyl-D-alanine carboxypeptidase DacB	Enzyme	DACB_ECOLI	INHIBITOR			DRUGBANK	CHEMBL
Penicillin-binding protein 4	Enzyme	Q5D1E9_STAAU				WOMBAT-PK
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5	Enzyme	Q9X6V7_PSEAI				WOMBAT-PK
Penicillin-binding protein 1	Enzyme	A1KS91_NEIMF				WOMBAT-PK
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6	Enzyme	Q7CHG0_YERPE				WOMBAT-PK
Streptokinase A	Enzyme	STRP_STRP1		EC50	6.90	WOMBAT-PK
Beta-lactamase class B VIM-2	Unclassified	Q9K2N0_PSEAI		Kd	4.92	CHEMBL
Beta-lactamase NDM-1	Enzyme	BLAN1_KLEPN		Kd	4.96	CHEMBL
Penicillin-binding protein 2	Enzyme	Q9X6V3_PSEAI				WOMBAT-PK
Beta-lactamase	Enzyme	Q6XEC0_KLEPN		Kd	6.07	CHEMBL

Showing 1 to 10 of 10 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
005166	NDDF
10829	IUPHAR_LIGAND_ID
119478-56-7	SECONDARY_CAS_RN
173661	MMSL
29561	RXNORM
387540000	SNOMEDCT_US
4021008	VUID
4021008	VANDF
441130	PUBCHEM_CID
5055	MMSL

Showing 1 to 10 of 23 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Meropenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0222	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	27 sections
Meropenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1390	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	27 sections
Meropenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1390	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	27 sections
Meropenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1391	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Meropenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1391	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Meropenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3412	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
MEROPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3000	INJECTION	500 mg	INTRAVENOUS	ANDA	30 sections
MEROPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3000	INJECTION	500 mg	INTRAVENOUS	ANDA	30 sections
MEROPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3000	INJECTION	500 mg	INTRAVENOUS	ANDA	30 sections
MEROPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3098	INJECTION	1 g	INTRAVENOUS	ANDA	30 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next